Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime Sells 8,000 Shares

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total transaction of $927,520.00. Following the completion of the transaction, the chief financial officer now owns 90,383 shares of the company’s stock, valued at approximately $10,479,005.02. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Andrew Guggenhime also recently made the following trade(s):

• On Thursday, July 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $81.17, for a total transaction of $649,360.00.

Vaxcyte Price Performance

Shares of NASDAQ PCVX opened at $115.18 on Friday. The company has a market cap of $12.86 billion, a PE ratio of -26.91 and a beta of 0.97. Vaxcyte, Inc. has a 12 month low of $44.20 and a 12 month high of $121.06. The company has a 50-day simple moving average of $89.12 and a 200-day simple moving average of $76.38.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($1.10) EPS for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.04. During the same quarter in the previous year, the company earned ($0.70) EPS. On average, analysts anticipate that Vaxcyte, Inc. will post -4.33 EPS for the current year.

Institutional Investors Weigh In On Vaxcyte

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Darwin Global Management Ltd. boosted its position in shares of Vaxcyte by 374.3% in the first quarter. Darwin Global Management Ltd. now owns 2,750,804 shares of the company’s stock worth $187,907,000 after acquiring an additional 2,170,845 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Vaxcyte by 15.2% in the first quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock worth $665,152,000 after acquiring an additional 1,284,883 shares during the last quarter. Norges Bank acquired a new stake in shares of Vaxcyte in the fourth quarter worth approximately $57,494,000. Capital Research Global Investors boosted its position in shares of Vaxcyte by 20.4% in the first quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock worth $282,839,000 after acquiring an additional 700,414 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its position in shares of Vaxcyte by 9.9% in the first quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock worth $524,117,000 after acquiring an additional 692,492 shares during the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Bank of America increased their price target on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Needham & Company LLC raised their target price on shares of Vaxcyte from $95.00 to $140.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Jefferies Financial Group raised their target price on shares of Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Mizuho raised their target price on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a report on Tuesday, September 10th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Thursday, June 20th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $147.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.